Media ReleasesImmutep

View All Immutep News


Immutep - Final Phase IIb AIPAC clinical trial results for Efti in MBC


• Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancer
• OS benefit trend in total population, with median survival benefit of +2.9 months from efti plus chemotherapy, compared to chemotherapy plus placebo
• Statistically significant and clinically meaningful OS benefit confirmed now in three predefined patient subgroups (patients < 65 years, low monocytes and luminal B) with improved data versus data presented in December 2020
• Survival benefit of +7.5 months, +19.6 months and +4.2 months in the < 65 years, low monocytes and luminal B subgroups, respectively. Reflects a benefit of > 50%, > 150% and > 33%, respectively.
• Efti increased circulating CD8 T cells which is significantly correlated with improved OS
• Investor webcast Wednessday, 17 November 2020, at 8.00 am Australian Eastern Daylight Time (AEDT), details below.

SYDNEY, AUSTRALIA - 10 November 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces final OS data from its Phase IIb AIPAC trial which are being presented in a late breaker presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 held from 10-14 November 2021.

227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC) were 1:1 randomised in the placebo-controlled, double-blind AIPAC study. The trial evaluated Immutep’s lead product candidate eftilagimod alpha (“efti”) in combination with paclitaxel chemotherapy (efti group, N=114) in comparison to a combination of placebo and paclitaxel chemotherapy (comparator group, N=113).

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.